Drug Profile
APS 001F
Alternative Names: APS-001FLatest Information Update: 17 May 2021
Price :
$50
*
At a glance
- Originator Anaeropharma Science
- Class Cytosine deaminase flucytosine gene therapies
- Mechanism of Action Enzyme induced prodrug activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 17 May 2021 Anaeropharma suspends a phase I/II trial in Solid tumours (Combination therapy, Late stage disease, Metastatic disease, Second line therapy or Greater) in USA (NCT01562626)
- 01 Apr 2017 Pharmacodynamics data from preclinical study in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
- 21 Dec 2015 Phase-I/II development is ongoing in USA